Patents by Inventor Miriam Verena BUJNY

Miriam Verena BUJNY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250082759
    Abstract: The invention lies in the field of treatment and prophylaxis of muscle wasting disorders, in particular the ones involving a genetic factor that can be targeted by a delivery of a therapeutic nucleic acid into the muscle cells. In line with the latter aspect, disclosed herein are pharmaceutical compositions and advantageous components thereof that substantially enhance the effective delivery and release of a therapeutic nucleic acid into the correct internal compartment of the muscle cell, such as the cytosol and/or the nucleus, in which compartment it can reach and act upon its genetic target. As disclosed herein, this substantially enhanced delivery and release is achieved by a provision of an endosomal-escape-enhancing saponin that is specifically targeted to muscle cells by covalent conjugation with a ligand of an endocytic receptor present on a muscle cell, into a pharmaceutical composition comprising a therapeutic nucleic acid.
    Type: Application
    Filed: December 20, 2022
    Publication date: March 13, 2025
    Inventors: Miriam Verena BUJNY, Ruben POSTEL, Guy HERMANS
  • Publication number: 20250057971
    Abstract: The invention lies in the field of treatment and prophylaxis of muscle wasting disorders, in particular the ones involving a genetic factor that can be targeted by a delivery of a therapeutic nucleic acid into the muscle cells. In line with the latter aspect, disclosed herein are pharmaceutical compositions and advantageous components thereof that substantially enhance the effective delivery and release of a therapeutic nucleic acid into the correct internal compartment of the muscle cell, such as the cytosol and/or the nucleus, in which compartment it can reach and act upon its genetic target. As disclosed herein, this substantially enhanced delivery and release is achieved by a provision of an endosomal-escape-enhancing saponin in the disclosed herein pharmaceutical compositions comprising therapeutic nucleic acids and muscle cell-targeting ligands.
    Type: Application
    Filed: December 20, 2022
    Publication date: February 20, 2025
    Inventors: Miriam Verena BUJNY, Ruben POSTEL, Guy HERMANS
  • Publication number: 20250051770
    Abstract: The invention lies in the field of treatment and prophylaxis of muscle wasting disorders, in particular the ones involving a genetic factor that can be targeted by a delivery of a therapeutic nucleic acid into the muscle cells. In line with the latter aspect, disclosed herein are pharmaceutical compositions and advantageous components thereof that substantially enhance the effective delivery and release of a therapeutic nucleic acid into the right internal compartment of the muscle cell, such as the cytosol and/or the nucleus, in which compartment it can reach and act upon its genetic target. As disclosed herein, this substantially enhanced delivery and release is achieved by a provision of an endosomal-escape-enhancing saponin in the disclosed herein pharmaceutical compositions comprising therapeutic nucleic acids and, optionally, muscle cell-targeting ligands conjugated therewith.
    Type: Application
    Filed: December 20, 2022
    Publication date: February 13, 2025
    Inventors: Miriam Verena BUJNY, Ruben POSTEL, Guy HERMANS
  • Patent number: 10703803
    Abstract: The present invention provides influenza neuraminidase (NA)-binding human antibodies, which are capable of specifically binding to and neutralizing at least one influenza B virus strain from the B/Victoria lineage and/or at least one influenza B virus strain from the B/Yamagata lineage, as well as antigen-binding fragment thereof. The invention furthermore relates to the use of said antibodies or antigen-binding fragments in the diagnosis, prophylaxis and/or treatment of influenza infection.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: July 7, 2020
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Miriam Verena Bujny, Remko Van Der Vlugt, Donata De Marco
  • Publication number: 20200002406
    Abstract: The present invention provides influenza neuraminidase (NA)-binding human antibodies, which are capable of specifically binding to and neutralizing at least one influenza B virus strain from the B/Victoria lineage and/or at least one influenza B virus strain from the B/Yamagata lineage, as well as antigen-binding fragment thereof. The invention furthermore relates to the use of said antibodies or antigen-binding fragments in the diagnosis, prophylaxis and/or treatment of influenza infection.
    Type: Application
    Filed: February 28, 2017
    Publication date: January 2, 2020
    Inventors: Miriam Verena BUJNY, Remko VAN DER VLUGT, Donata DE MARCO
  • Patent number: 10174127
    Abstract: The present invention provides influenza neuraminidase (NA)-binding human antibodies, which are capable of neutralizing at least one influenza A virus strain comprising NA of the N1 subtype, and antigen-binding fragments thereof. In certain embodiments, the antibodies or antigen-binding fragments furthermore are capable of neutralizing at least one influenza A virus strain comprising NA of the N2 subtype. The invention furthermore relates to the use of said antibodies or antigen-binding fragments in the diagnosis, prophylaxis and/or treatment of influenza infection.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: January 8, 2019
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Miriam Verena Bujny, Remko Van Der Vlugt
  • Publication number: 20180016348
    Abstract: Influenza neuraminidase (NA)-binding human antibodies, which are capable of neutralizing at least one influenza A virus strain containing NA of the N1 subtype, and antigen-binding fragments thereof are described. Certain antibodies or antigen-binding fragments described herein furthermore are capable of neutralizing at least one influenza A virus strain comprising NA of the N2 subtype. Also described is the use of said antibodies or antigen-binding fragments in the diagnosis, prophylaxis and/or treatment of influenza infection.
    Type: Application
    Filed: February 4, 2016
    Publication date: January 18, 2018
    Inventors: Miriam Verena BUJNY, Remko VAN DER VLUGT